The conversation discusses finding sources of Dutasteride in Europe for mesotherapy to treat hair loss. It also mentions using Minoxidil, Finasteride, and RU58841 as treatments.
The user maintained hair with minoxidil, alfatradiol, and fluridil after stopping finasteride due to erectile dysfunction. They recently added pyrilutamide and are seeking feedback on its effectiveness after six months of use.
A user started taking Musely men's bloom hair pill, which contains minoxidil, dutasteride, and vitamins, and noticed a stop in hair shedding after switching from other hair loss treatments like hims and Keeps. They are questioning the effectiveness of the Musely pill due to its lower dosage of active ingredients and are curious about others' experiences with the product.
Finasteride prescriptions in France now require an annual certificate acknowledging psychiatric and sexual risks, as the European Medicines Agency recognizes these risks. The conversation discusses the potential mental health effects of Finasteride, with some users reporting side effects and others questioning the statistical significance of these findings.
The user used finasteride but stopped due to side effects, then used topical minoxidil for 13 months, and later added KX826/pyrilutamide for 8 months. They experienced shedding after starting pyrilutamide and use minoxidil and KX826 once daily.
Exosomes, cetirizine, melatonin, latanoprost, and caffeine are discussed as potential hair loss treatments. There is skepticism about the effectiveness of exosomes, especially in topical form, but some users report positive results.
Hims chewable oral minoxidil may be less effective due to its form and dosage of 2.5 mg. The effectiveness is questioned because the source criticizing it sells a competing product.
A user experienced a tingling sensation in their mouth after taking a cut finasteride pill, possibly due to inactive ingredients like mannitol or sodium lauryl sulfate. Tingling is not a common side effect or typical allergy sign, but monitoring for unusual reactions is advised.
Breezula's phase 3 results are expected soon, but its release is likely delayed until 2027 or 2028. The discussion highlights the need for more hair growth stimulants like AMP-303 and PP-405, as current treatments like Dutasteride effectively stop hair loss but don't regrow hair.
A user reported seeing hair regrowth in less than two months after starting a Hims hybrid chewable containing 1.2mg finasteride, 3mg minoxidil, and 2.5mg biotin. They experienced initial shedding but no other side effects and were prescribed the treatment through Hims.
The user has been using 1.25 mg of oral minoxidil and finasteride since September 2025 to address diffuse hair thinning, and is considering trying a new shampoo. Other users suggest increasing the minoxidil dose and trying dutasteride.
The conversation is about the availability of WINLEVI, a hair loss treatment, and the possibility of getting it compounded. The user is seeking information on when they can obtain the treatment.
A user experienced side effects from hair loss treatment and contacted HIMS, resulting in their subscription being canceled. They were taking Zinc to manage symptoms and are considering consulting a doctor.
A user is considering a long-term hair loss treatment stack including Dutasteride, Finasteride, and oral Minoxidil, and is concerned about potential liver damage. Some responses suggest the stack is excessive, while others believe it's not harmful to the liver, but recommend regular blood work to monitor health.
Hope Medicine's announcement of the HMI-115 Phase II clinical trial for androgenetic alopecia in China; other related trials have been conducted or are ongoing in different countries, including Australia, US, and Europe. There is speculation that the product may be accepted across borders without additional testing.
The user discusses their hair regrowth success with minoxidil, red light therapy, massage, and derma stamping but expresses concerns about using finasteride due to potential side effects. They are interested in using clascoterone as a topical treatment for hair loss and are exploring the possibility of creating a topical formula from raw clascoterone powder.
The conversation discusses the importance of Finasteride for hair loss treatment in the EU and encourages individuals to voice their support to the EMA. It highlights the potential influence of public input on regulatory decisions.
The FDA policy change may speed up approval for hair loss drugs like PP405, VDPHL-01, and Breezula by potentially eliminating the need for a second confirmatory Phase 3 trial. Approval timelines could be as early as 2028 for some treatments if Phase 3 results are strong.
User is experiencing increased sebum, dandruff, and acne after taking a supplement containing biotin, iron, zinc, and calcium pantothenate along with finasteride. They are questioning if biotin is the cause and whether they should stop taking it.
The user experienced erectile dysfunction from oral finasteride and is considering alternatives like topical high-dose finasteride, RU58841, topical Latanoprost, and oral Minoxidil. Blood tests showed changes in testosterone and DHT levels, and the endocrinologist advised stopping finasteride.
Dutasteride effectively reduces DHT levels and significantly increases testosterone levels. Users are cautious about adding oral minoxidil due to potential heart issues and are considering dosage adjustments with medical guidance.
A pharmacy error resulted in a finasteride solution being 100 times stronger than prescribed, not 10,000 times as initially feared. OP is advised to contact the pharmacy to clarify the preparation before traveling.
The user experienced hair improvement using a topical finasteride, minoxidil, and tretinoin combo, along with supplements like zinc, copper, magnesium, vitamin D3, K2, iodine, and boron. They believe these changes are due to addressing mineral deficiencies and possibly thyroid issues, despite skepticism from others.
Finasteride is not linked to a 60% risk of persistent sexual dysfunction; this figure applies only to those already experiencing sexual issues. Most users do not have side effects, and the study's methodology is criticized for selection bias.
You cannot donate blood if you are taking finasteride or dutasteride due to potential risks to pregnant women. Finasteride has a shorter wait time to donate blood compared to dutasteride, and both oral and topical forms can disqualify you from donating.
The conversation confirms that to make a 5% RU58841 solution, 1.5 grams should be added to 30 mL of KB Solution. The discussion involves calculating the correct dosage for hair loss treatment.
Clascoterone is a topical treatment for androgenetic alopecia, showing modest to moderate hair regrowth, and may be available by 2027-2028. It is considered safer than finasteride, with discussions on its effectiveness compared to RU58841 and pyrilutamide.
TDM-105795 is a potential hair growth stimulant that works differently from minoxidil and could be used alongside it for enhanced growth. It completed phase 2 trials in 2024, with a medium to high chance of release in 2026, but lacks recent updates or phase 3 trial information.
The user switched from Pyrilutamide to RU58841, changed their Minoxidil solution, and continued using low-dose Finasteride, derma rolling, and specific shampoo. They asked others about their plans after Pyrilutamide's disappointing results.